(S)-Tert-Butyl 2-(5-Bromo-1H-Imidazol-2-Yl)Pyrrolidine-1-Carboxylate

The chiral building block (S)-tert-butyl 2-(5-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate functions primarily as a late-stage diversification handle and stereodefined scaffold in small-molecule active pharmaceutical ingredient (API) synthesis. The tert-butoxycarbonyl (Boc) group preserves pyrrolidine nitrogen nucleophilicity until a programmed deprotection step, while the 5-bromo substituent on the imidazole ring enables a broad range of transition-metal-catalyzed cross-couplings—Suzuki, Negishi, and Buchwald-Hartwig aminations—under conditions compatible with the acid-labile N-Boc moiety. Regulatory starting material designation under ICH Q11 is typically evaluated through a chemical transformation step count of three or more from the final API, and the introduction of this intermediate at an appropriate stage allows sponsors to define the GMP boundary just upstream of the pivotal coupling step, thereby simplifying the supplier qualification audit trail. Residual elemental impurity risk is concentrated in the palladium and copper content after the coupling step; finished API manufactured using this intermediate must meet the concentration-based limits for oral permitted daily exposure specified in ICH Q3D Guideline for Elemental Impurities, Table A.2.1, with Pd controlled to 10 µg/g and Cu to 300 µg/g unless otherwise justified by a risk assessment.

How does the chiral pyrrolidine-imidazole core affect kinase hinge-binding geometry?

In Type II and Type I½ kinase inhibitor programs targeting the DFG-out or intermediate conformation of the activation loop, the (S)-configured pyrrolidine ring imparts a defined vector angle between the imidazole hinge binder and the extended hydrophobic pocket. When incorporated into a macrocyclic or extended linear scaffold, the stereocenter at the 2-position of the pyrrolidine dictates the presentation of the lipophilic tail toward the allosteric back pocket. The bromoimidazole moiety in this intermediate is typically subjected to a palladium-mediated Suzuki coupling with a para-functionalized arylboronate—operationally conducted at 1.05–1.15 equivalents of the bromo intermediate relative to the boronate coupling partner—to introduce a fluorophenyl or pyrimidinyl extension before the Boc group is cleaved. Process equipment for the coupling at 20-kg input of the bromo compound commonly employs a 2000-L glass-lined reactor with an anchored paddle agitator running at 85–95 rpm tip speed; the organic phase after aqueous workup is passed through a cartridge filter loaded with 3% wt/wt activated carbon (relative to theoretical product) and a 0.45-µm PTFE membrane to remove colloidal palladium. ICH M7 (Assessment and control of DNA reactive (mutagenic) impurities) requires control of the bromoimidazole starting material itself as a potential alkylating agent; Ames test data (OECD 471, five-strain panel) conducted on the isolated intermediate typically yields negative results, but a control threshold of ≤1.5 mg/day for structurally related potential genotoxic impurities is applied downstream. The coupling product is then subjected to Boc deprotection using 3.5–4.0 M HCl in 1,4-dioxane at 15–20°C with jacket cooling capacity of −25°C brine; the hydrochloride salt precipitates directly from the reaction mixture and is isolated by centrifuge filtration and dried in a conical vacuum dryer at 40°C / 10 mbar for 12 h. Final API form is typically a besylate or tosylate salt prepared in a subsequent step, qualified against USP <231> for heavy metals and subjected to enantiomeric purity determination by chiral HPLC (Chiralpak IA, 250 × 4.6 mm, hexane/ethanol/0.1% TFA).

The synthesis of an orally bioavailable FXR (farnesoid X receptor) agonist for biopsy-confirmed NASH with stage F2–F3 fibrosis proceeds through a convergent route that positions the (S)-tert-butyl 2-(5-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate at the junction point between a southern carboxylic acid-bearing fragment and a northern lipophilic tail. Unlike the kinase inhibitor workflows described above, the bromo substituent here is not engaged in a direct C–C bond formation; instead the imidazole nitrogen is protected in situ as a SEM or trityl group prior to Negishi coupling of a pre-formed organozinc reagent derived from the bromoimidazole, which requires the bromo intermediate to be used at 1.25–1.30 equivalents relative to the electrophilic coupling partner to compensate for protodehalogenation losses during zinc insertion. The zinc insertion itself is performed in a dedicated 50-L Hastelloy C-276 reactor under THF/anhydrous NMP (9:1 v/v) with sub-surface argon sparging to maintain dissolved oxygen below 12 ppm; a thermocouple probe with 0.1°C resolution tracks the induction period, which typically initiates between 48°C and 52°C as evidenced by a 3–5°C exothermic excursion. Regulatory oversight under FDA 21 CFR Part 211 Subpart D requires in-process bioburden testing of the filtered coupling solution prior to batch distillation, with a specification of <100 CFU/mL and absence of specified pathogens per USP <61>/<62>. After the coupling, the Boc group is retained through two downstream amidation steps to maintain solubility of the growing molecule in the EtOAc/heptane crystallization system; its removal with TFA in DCM (25% v/v TFA, 0–5°C) is postponed until the penultimate step, at which point the liberated pyrrolidine undergoes immediate salt formation with fumaric acid (1.05 equiv.) in isopropanol/water. The terminal API is a hemifumarate dihydrate crystalline form (Form A) characterized by XRPD, with a release specification for achiral purity of ≥99.7% area by HPLC (C18, 150 × 3.0 mm, gradient 10–95% acetonitrile in 0.1% trifluoroacetic acid) and chiral purity of ≥99.0% ee. Drying in a tumble dryer with vacuum ramps of 5 mbar/h to a final Loss on Drying of 2.3–2.8% corresponds to a stoichiometric dihydrate.

When Boc cleavage kinetics dictate crystallization purity in continuous manufacturing

Continuous manufacturing campaigns for an inhaled JAK inhibitor—administered as a suspension for nebulization in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome—use this bromoimidazole intermediate as the multicomponent reaction entry point for constructing the tricyclic core. The manufacturing authorization holder filed the continuous process under ICH Q13 (Continuous Manufacturing of Drug Substances and Drug Products), requiring the GMP starting material to be pumped as a 1.0 M solution in DMF with a residence time of 45 min in the plug-flow reactor coil maintained at 90 ± 2°C with back-pressure regulation of 7.0 bar. Exactly 1.00 equivalent of the bromo compound is metered against the in situ-formed Grignard coupling partner via Coriolis flow meters calibrated to ±0.5% accuracy; deviation beyond 1.5% triggers automated diversion to waste. The most critical quality attribute during the subsequent Boc deprotection in a continuous stirred-tank cascade is the mean residence time distribution, because the acid-labile benzylic ether in the tricyclic system degrades if the HCl/dioxane residence exceeds 22 min. Monitoring is performed by an online ReactIR with a DiComp diamond ATR probe collecting spectra at 15 s intervals in the region 1800–1650 cm⁻¹ to track the carbonyl stretching frequency shift from 1748 cm⁻¹ (Boc C=O) to baseline; when integrated peak area drops below 2% of the initial value, the stream is quenched with aqueous sodium carbonate. The hydrochloride salt is isolated via continuous oscillatory baffled crystallization at 40°C and a supersaturation ratio of 1.15, yielding mean crystal size of 45 µm with span (<1.8). The finished drug substance is micronized to D₉₀ <5 µm by jet milling under nitrogen at 8 bar, filled into HDPE bottles as an inhalation-grade powder for extemporaneous reconstitution with saline. European Pharmacopoeia (Ph. Eur. 10.8) compliance for the API mandates a specified limit for N-nitrosamine impurities at ≤26.5 ng/day based on the ICH M7 acceptable intake for a ≤10-year treatment duration; the synthetic route was confirmed nitrosamine-free by spiking studies with N-nitroso-pyrrolidine at the 0.03 ppm level using LC-MS/MS operated in APCI positive mode.

A structurally enabled antiviral program targeting the cap-snatching endonuclease activity of influenza A (H1N1 and H3N2) and influenza B polymerases relies on a lead series whose pharmacophore features a rigidified pyrrolidine-imidazole core occupying the P1 pocket near the two-metal catalytic center. In this class, the (S)-tert-butyl 2-(5-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate is converted into the final active moiety through a sequential Buchwald-Hartwig amination and subsequent sulfonamide formation. The bromoimidazole intermediate is employed at 1.00–1.03 equivalents relative to the C5′-aminated heterocycle coupling partner; an excess above 1.05 equivalents results in a difficult-to-purge homocoupled imidazole dimer that co-elutes with the product on normal-phase silica (Rf difference <0.03 in hexane/ethyl acetate 1:1). The amination is run in a 400-L stirred Hastelloy reactor at 95–100°C with Pd(OAc)₂ (1.2 mol%) and BINAP (1.8 mol%) under 5 psig nitrogen, consuming the limiting amine within 14–16 h as tracked by in-line UV at 310 nm. Residual palladium is scavenged by a polymer-bound trimercaptotriazine resin bed (flow rate 2 bed volumes/h) integrated into the post-reaction filtration loop; the Pd concentration in the eluate stream is measured by on-line X-ray fluorescence with a limit of quantitation of 0.5 ppm. After solvent switch to methyl tert-butyl ether and seeding with 0.5 wt% of previously isolated material, the intermediate crystallizes as a thermodynamically stable anhydrous Form II, which is dried in a filter-dryer under a nitrogen sweep at 50°C jacket temperature to a water content of <0.3% (Karl Fischer, volumetric). Regulatory filings in Japan require compliance with JP 18 General Tests for Heavy Metals and reference to the MHLW guideline on residual solvents (PSEHB/ELD Notification No. 0315); the acetic acid from the Pd(OAc)₂ catalyst is controlled in the final API to <5000 ppm, well below the ICH Q3C Class 3 limit of 0.5%. The deprotected pyrrolidine is ultimately elaborated into a piperazinyl sulfonamide prodrug, and the final dosage form is a lyophilized powder for injection presented as a 10-mg/vial unit with hydroxypropyl-β-cyclodextrin as a solubilizing excipient.

Diastereomeric ratio drift during Boc removal in the presence of unprotected imidazole NH: a process robustness study

Triazole- and imidazole-containing scaffolds designed for dual IDO1/TDO inhibition in checkpoint-refractory melanoma require the (S)-pyrrolidine ring to remain configurationally stable throughout a sequence that includes an early-stage bromine–lithium exchange and formylation, a transformation rarely conducted on N-Boc-protected 2-bromoimidazoles because of competing ortho-metalation at the pyrrolidine C-3 position. To suppress this undesired pathway, the manufacturing process executes the exchange at −78 ± 3°C in a 3:1 THF/toluene mixture using n-BuLi (1.08–1.12 equivalents, hexane solution) and an in-line FTIR probe monitoring the disappearance of the C–Br stretching band at 612 cm⁻¹; the formylation quench with N-formylmorpholine is triggered when the absorbance at this wavenumber drops to 2% of the initial intensity. Following borohydride reduction of the resulting aldehyde, the alcohol is converted to a mesylate and displaced with a tetrahydroisoquinoline fragment through a nucleophilic substitution that requires the Boc-protected pyrrolidine nitrogen to not participate. The pyrrolidine stereocenter is vulnerable to epimerization only after the Boc group is removed with 1.5 M HCl in cyclopentyl methyl ether at 0–5°C; diastereomeric ratio (dr) measured by ¹⁹F NMR of a Mosher's amide derivative of the crude reaction mixture must be ≥98.5:1.5 before the subsequent acylation with an α-fluoroacrylamide warhead. A process analytical technology (PAT) strategy developed in accordance with FDA guidance incorporates a portable Raman immersion probe (excitation wavelength 785 nm, spectral range 200–2400 cm⁻¹) to monitor the C–O stretching modes of the tert-butyl group (845 cm⁻¹ and 1250 cm⁻¹) and ensure that less than 0.3 area% of Boc-protected species remains before the pH is raised to 8.0–8.5 for the acylation. The final monomeric IDO1 inhibitor API is a free base with a softening point of 118°C (DSC, 10°C/min), intended for direct encapsulation in HPMC capsules as a 50-mg oncology therapy. The quality target product profile (QTPP) references ICH Q6A decision tree #4 for polymorphic identity and requires demonstration of bioequivalence between the amorphous solid dispersion and the crystalline form in a fasted-state simulated gastric fluid (FaSSGF) with a discriminatory dissolution method at 75 rpm, USP Apparatus 2.